{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"To assess the very good partial response rate (\\>90% reduction in serum IgM from baseline)","groups":[{"description":"PCI-32765; ibrutinib\n\nPCI-32765: Taken orally, once daily in the morning","id":"OG000","title":"Treatment Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 years","title":"Very Good Partial Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}